Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study (Q33622785)

28 July 2017

title

Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study (English)

1 reference

sulfamethoxazole/trimethoprim

28 July 2017

0 references

1 reference

Jacques Fellay

8

0 references

Swiss HIV Cohort Study

12

object named as

Swiss HIV Cohort Study

1 reference

28 July 2017

6

Manuel Battegay

1 reference

28 July 2017

7

Alexandra Calmy

1 reference

28 July 2017

4

Hansjakob Furrer

1 reference

28 July 2017

11

Bruno Ledergerber

1 reference

28 July 2017

2

A Sarah Walker

1 reference

28 July 2017

Barbara Hasse

1

1 reference

28 July 2017

Jan Fehr

3

1 reference

28 July 2017

Matthias Hoffmann

5

1 reference

28 July 2017

Caroline Di Benedetto

9

1 reference

28 July 2017

Rainer Weber

10

1 reference

28 July 2017

language of work or name

English

0 references

publication date

10 February 2014

1 reference

Antimicrobial Agents and Chemotherapy

28 July 2017

published in

1 reference

28 July 2017

volume

58

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

2363-2368

1 reference

Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Sulfamethoxazole enhances the antimycobacterial activity of rifampicin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Tuberculosis and trimethoprim-sulfamethoxazole

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Mycobacterium tuberculosis and sulfamethoxazole susceptibility

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Cohort profile: the Swiss HIV Cohort study

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023723

Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24514096

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24514096

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24514096

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.01868-13

1 reference

28 July 2017

1 reference

28 July 2017

1 reference